Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2026 10:30 ET | Source: Palvella Therapeutics Inc.

Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting

Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the...
March 27, 2026 10:13 ET | Source: BCC Research LLC

AI Is Reshaping Neuroprotective Drug Discovery Market: New BCC Research Pulse Report Maps the Investment and Innovation Landscape

The neuroprotective agents market in North America is growing at approximately 4.5% CAGR through 2030, with AI-driven approaches.
March 27, 2026 10:10 ET | Source: Aclaris Therapeutics, Inc.

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
March 27, 2026 09:33 ET | Source: California Institute for Regenerative Medicine (CIRM)

First therapy funded by California taxpayer dollars is approved to treat rare childhood disorder

South San Francisco, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- The California Institute for Regenerative Medicine (CIRM) celebrates a major milestone in the agency's 21-year history: the first...
March 27, 2026 09:00 ET | Source: Navigator Medicines INC

Navigator Medicines Advances NAV-240 into Phase 2a and NAV-242 into the Clinic, Supported by New Positive Data Presented at American Academy of Dermatology (AAD) Annual Meeting 2026

First Patient Dosed (FPD) in Phase 2a MAINSAIL Trial of NAV-240 in Hidradenitis Suppurativa (HS)Phase 1b Multiple Ascending Dose Study Demonstrates Favorable Profile for NAV-240 First Participant...
March 27, 2026 08:00 ET | Source: OnKure Therapeutics, Inc.

OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies

-- Financing led by Access Biotechnology with participation from new and existing investors -- Financing to support advancement of two next-generation PI3Kα pan-mutant inhibitors for breast cancer...
March 27, 2026 08:00 ET | Source: OXB

OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards

Oxford, UK – 27 March 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene...
March 27, 2026 08:00 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : La formulation sous-cutanée de Sarclisa de Sanofi, administrée via un injecteur portable, est recommandée par le CHMP pour approbation dans l'UE dans le traitement du myélome multiple

La formulation sous-cutanée de Sarclisa de Sanofi, administrée via un injecteur portable, est recommandée par le CHMP pour approbation dans l'UE dans le traitement du myélome multiple ...
March 27, 2026 08:00 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma

Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma Recommendation based on positive results demonstrating...
March 27, 2026 07:56 ET | Source: Arletta Pharma Solutions

Arletta Pharma Solutions Announces Positive Results from Phase II Clitoral Doppler Duplex Ultrasound Study of Lybrido™ Combination Targeting Female Sexual Dysfunction

Arletta Pharma reports >60% clitoral blood flow improvement with Lybrido™ in Phase II study, achieving statistical significance in women with FSIAD.